Benzodiazepines (BZs), which are among the most widely prescribed psychoactive drugs, are subject to abuse, and can cause tolerance and dependence. Though BZs act by binding to specific neuronal receptors, the binding site is not that of a neurotransmitter. Rather, it is a modulatory site on the receptor for GABA, the major inhibitory neurotransmitter. BZs increase the ability of GABA to open Cl channels, increasing inhibitory neurotransmission. BZ/GABA receptors show remarkable molecular heterogeneity. BZs do not all interact with the receptors uniformly, and this is reflected in tolerance and dependence. Tolerance develops more rapidly for some drug actions than others, and there are differences among BZs in degree and rate of tolerance or dependence development. Even after a given BZ treatment, the degree of tolerance shown depends on the particular BZ chosen for testing. Differences among BZs are probably due to differing interactions of particular BZs with GABA receptors during and after chronic treatment. This project will study the role of changes in BZ/GABA receptors in tolerance and physical dependence. Several drugs that act at the BZ/GABA receptor will be examined in rats treated with either flurazepam or with diazepam. These treatments are known to cause differing patterns of tolerance and dependence, as well as differing neurochemical changes. The BZ/GABA receptor will be studied by specific binding of BZs to tissue obtained from particular brain regions of tolerant rats. Changes in BZ/GABA receptor numbers and characteristics may result from modifications in the combinations of subunits that neurons assemble to form these receptors. Regional brain mRNA expression for the many GABA receptor subunits will be examined and compared to the dose and time requirements for producing tolerance and dependence. The protein product will also be examined using an antibody specific for one of the major subunits of the GABA receptor. Results from the behavioral and biochemical experiments will be examined, and the patterns of changes over time and among brain regions will be compared to help define the role of the GABA receptor in chronic BZ actions.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
2R01DA002194-16A1
Application #
2116519
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
1985-02-01
Project End
1998-01-31
Budget Start
1995-03-15
Budget End
1996-01-31
Support Year
16
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Toledo
Department
Physiology
Type
Schools of Medicine
DUNS #
807418939
City
Toledo
State
OH
Country
United States
Zip Code
43614
Dong, Yu; Rosenberg, Howard C (2004) Brief seizure activity alters Ca2+/calmodulin dependent protein kinase II dephosphorylation and subcellular distribution in rat brain for several hours. Neurosci Lett 357:95-8
Dong, Yu; Rosenberg, Howard C (2004) Prolonged changes in Ca2+/calmodulin-dependent protein kinase II after a brief pentylenetetrazol seizure; potential role in kindling. Epilepsy Res 58:107-17
Li, M; Szabo, A; Rosenberg, H C (2001) Evaluation of native GABA(A) receptors containing an alpha 5 subunit. Eur J Pharmacol 413:63-72
Li, M; Szabo, A; Rosenberg, H C (2000) Down-regulation of benzodiazepine binding to alpha 5 subunit-containing gamma-aminobutyric Acid(A) receptors in tolerant rat brain indicates particular involvement of the hippocampal CA1 region. J Pharmacol Exp Ther 295:689-96
Walsh, L A; Li, M; Zhao, T J et al. (1999) Acute pentylenetetrazol injection reduces rat GABAA receptor mRNA levels and GABA stimulation of benzodiazepine binding with No effect on benzodiazepine binding site density. J Pharmacol Exp Ther 289:1626-33
Zhao, T J; Li, M; Chiu, T H et al. (1998) Decreased benzodiazepine binding with little effect on gamma-aminobutyric acid binding in rat brain after treatment with antisense oligodeoxynucleotide to the gamma-aminobutyric acidA receptor gamma-2 subunit. J Pharmacol Exp Ther 287:752-9
Zhao, T J; Rosenberg, H C; Chiu, T H (1996) Treatment with an antisense oligodeoxynucleotide to the GABAA receptor gamma 2 subunit increases convulsive threshold for beta-CCM, a benzodiazepine ""inverse agonist', in rats. Eur J Pharmacol 306:61-6
Tersigni, T J; Rosenberg, H C (1996) Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA. Brain Res 733:184-92
Rosenberg, H C (1995) Differential expression of benzodiazepine anticonvulsant cross-tolerance according to time following flurazepam or diazepam treatment. Pharmacol Biochem Behav 51:363-8
Wu, Y; Rosenberg, H C; Chiu, T H (1995) Rapid down-regulation of [3H]zolpidem binding to rat brain benzodiazepine receptors during flurazepam treatment. Eur J Pharmacol 278:125-32

Showing the most recent 10 out of 43 publications